If you’ve ever stared at a kratom label and noticed “7-hydroxymitragynine” in the fine print, you’ve probably wondered whether that specific alkaloid is actually legal, especially with all the headlines about bans, FDA crackdowns, and “synthetic kratom” scares. This isn’t just a niche question anymore. As states ramp up kratom consumer protection laws and federal agencies focus on high-potency derivatives, the legal status of 7-hydroxymitragynine (often shortened to 7-OH) is becoming its own separate battleground from regular kratom leaf.
In this guide, we’ll walk through how 7-hydroxymitragynine is treated at the federal level, how that differs from natural kratom, and then zoom in on the state-by-state landscape so you can understand where things stand right now. You’ll see why there’s a growing split between natural kratom products with naturally occurring alkaloid levels and concentrated or synthetic 7-OH products that regulators increasingly treat like opioids. Along the way, we’ll tie this into kratom lab testing, COAs, state-level kratom acts, and what “safe” looks like from a legal perspective. By the end, you’ll have the tools to read a label, interpret a Certificate of Analysis, and assess your risk before ever hitting “checkout.”
Let’s start with the basics. Kratom (Mitragyna speciosa) is a tropical tree whose leaves naturally contain dozens of alkaloids, but the two that get the most attention are mitragynine and 7-hydroxymitragynine. Mitragynine is usually the dominant alkaloid by percentage, while 7-OH is present in much smaller amounts in natural leaves. Despite that, 7-OH is believed to be considerably more potent at opioid receptors, which is exactly why it’s become the focal point for the FDA, DEA, and some state lawmakers.
In normal, traditionally prepared leaf (such as simple crushed leaf or mild tea), 7-OH is present only at trace or low levels relative to mitragynine. But modern extraction techniques, synthetic conversions, and high-potency concentrates can push those levels far beyond what would ever be found in a raw leaf from a farm in Southeast Asia. That’s where the legal trouble really starts. Regulators see a big difference between a plant product with naturally low 7-OH content and a lab-made or heavily concentrated 7-OH extract that behaves more like a powerful opioid.
Because of this, you’ll see laws and regulations that do something very specific: they don’t just talk about “kratom” in general. They call out 7-hydroxymitragynine by name, restrict synthetic versions, or cap the allowable percentage in finished products. In our own lab review of COAs and product labels, we’ve seen that reputable vendors now routinely highlight 7-OH levels, not just mitragynine, because customers and regulators are closely watching those numbers. According to public FDA communications and legal analyses, the government’s current priority is curbing concentrated or synthetic 7-OH, not banning every bag of kratom leaf on the shelf.
From a federal standpoint, kratom itself is still not scheduled under the Controlled Substances Act, despite earlier attempts and a failed move by the DEA in 2016 to place mitragynine and 7-OH into Schedule I. That means, as of early 2026, natural kratom products remain technically lawful at the federal level, even though the FDA has never approved kratom as a drug or dietary ingredient and has repeatedly warned consumers about safety concerns. The federal picture is messy: legal to possess, but under constant regulatory scrutiny.
The big recent shift came in 2025, when the FDA publicly announced that it had recommended scheduling 7-hydroxymitragynine, specifically in its concentrated or derivative forms, under the Controlled Substances Act. Legal and regulatory summaries note that the agency’s July 2025 evaluation framed 7-OH as a high-risk, opioid-like substance that lacks accepted medical use, fitting the criteria for Schedule I. Importantly, those same discussions emphasized that the target is not traditional whole-leaf kratom, but rather concentrated or synthetic 7-OH products that push potency far beyond natural levels.
Right now, that FDA recommendation still has to go through the DEA scheduling process, which means that federally, 7-OH is in a kind of legal limbo: not yet a nationally scheduled controlled substance on its own, but clearly in the crosshairs. Federal agencies have also made clear that 7-OH is not an approved ingredient in any drug, dietary supplement, or conventional food, which means products that market 7-OH directly are already vulnerable under existing misbranding and adulteration rules. So even before formal scheduling, companies dealing in concentrated 7-OH face a serious enforcement risk.
In practice, this creates a two-track federal reality. On one track, raw or minimally processed kratom leaf products exploit the gap left by the lack of formal scheduling but still operate under the FDA’s critical gaze. On the other track, concentrated or synthetic 7-OH products are being treated more like quasi-opioids, with higher enforcement interest and a clear push toward eventual scheduling. When you see headlines about federal crackdowns, it’s usually that second track. In our own reading of regulatory memos and legal advisories, the pattern is obvious: the more a product resembles a potent, isolated 7-OH drug, the more likely it is to invite trouble.
While federal law still officially leaves kratom unscheduled, states have not waited around. Over the last few years, more legislatures have either banned kratom outright, adopted Kratom Consumer Protection Acts (KCPAs), or introduced special rules targeting synthetic or high-7-OH products. A 2026 analysis of state laws noted that, as of January 2026, roughly 30 states, plus D.C., regulate kratom in some way, ranging from full bans to age limits and testing standards. That’s a massive jump from the early days when kratom was either ignored or quietly tolerated.
In that patchwork, 7-hydroxymitragynine has become a specific focal point. Some states simply lump 7-OH in when they schedule “kratom” as a controlled substance. Others draw a line between natural kratom leaf (with regular, low 7-OH levels) and synthetic or concentrated 7-OH products. A handful of states already cap allowable 7-OH content or ban “synthetic kratom” extracts altogether, using 7-OH as a proxy marker for dangerously high potency. We’ve seen the same pattern again and again in state-level updates: leave the plant alone or regulate it, but isolate 7-OH and treat it like an opioid threat.
This means you can’t just ask “Is kratom legal here?” and assume the answer covers 7-OH. A state might allow regulated kratom leaf but ban synthetic 7-OH outright. Another state might treat kratom and 7-OH the same and schedule both. A third might technically remain legal, but have bills in the pipeline to restrict them soon. If you’re a consumer, that’s confusing. If you’re a vendor, that’s a compliance nightmare. In our own policy tracking, we’ve noticed that “7-OH” increasingly appears as its own line item in statutes, rather than just a passing mention under a generic “kratom” label.
Let’s walk through the broad categories, then dive into specific examples. Bear in mind that local bans (counties, cities) can be stricter than state law, so the safest move is always to check your local jurisdiction on top of statewide rules.
Some states have taken the hard line: they’ve classified kratom and its main alkaloids, including mitragynine and 7-hydroxymitragynine, as controlled substances. In these places, both kratom and 7-OH are effectively illegal to possess, sell, or distribute, often under Schedule I designations at the state level.
Common examples (based on recent legal summaries and state-by-state breakdowns) include:
Indiana – Treats kratom’s primary alkaloids, including 7-OH, as Schedule I substances under state law.
Vermont has banned kratom and 7-OH through its controlled substance framework.
Some other states (like Louisiana) have recently moved to full kratom bans that include 7-OH, often with effective dates in 2025.
In these jurisdictions, the legal status of 7-hydroxymitragynine is straightforward but harsh. Because 7-OH is explicitly tied to kratom in the scheduling language, any kratom product with naturally occurring 7-OH is implicated, and concentrated or synthetic 7-OH is even more clearly in violation. According to legal analyses, these bans don’t usually carve out a special exception for “low 7-OH levels,” so arguing that your product is “just natural kratom” won’t help much in a courtroom.
From a practical standpoint, if you live in one of these states, the safest assumption is that both kratom and 7-hydroxymitragynine are illegal, regardless of how they’re marketed. No amount of COA paperwork or third-party lab testing will transform a banned substance into a legal one in those jurisdictions.
A growing number of states have gone down a more nuanced path: they keep kratom legal but regulate it through Kratom Consumer Protection Acts or similar statutes. These laws typically address age restrictions, labeling, lab testing, and contamination standards. Increasingly, they also address 7-hydroxymitragynine levels, especially with synthetic or highly concentrated forms.
Here are a few notable patterns drawn from recent state law roundups:
Nevada and Utah were early adopters of KCPA-style legislation, requiring kratom products to meet testing, labeling, and purity standards. Those frameworks indirectly regulate 7-OH by limiting certain alkaloid contents and cracking down on adulterated or synthetic products.
Georgia and Missouri have KCPA-style rules that restrict synthetic alkaloids and set boundaries on 7-OH content, aiming to keep products closer to natural leaf profiles.
Several states (like Maryland and Texas) now explicitly limit 7-OH percentages or ban synthetic derivatives while allowing natural kratom, essentially splitting the legal status between plant and potent derivative.
One summary of 7-OH regulations highlighted that Texas, for example, moved to ban synthetic kratom products and set a ceiling on 7-OH content (e.g., less than 2 percent) in kratom items beginning September 2025, clearly signaling that regulators see high 7-OH levels as an unacceptable risk. Other states with KCPAs use similar mechanisms, either by capping total alkaloid content or by outright forbidding synthetic 7-OH derivatives.
For consumers, regulated states are often where you’ll see the most robust lab testing and COA culture. Vendors typically publish COAs that show mitragynine and 7-OH levels, along with heavy-metal and microbial testing, to demonstrate compliance. In our testing and review of real COAs, we’ve noticed that reputable vendors in KCPA states aim to keep 7-OH levels aligned with what you’d see in traditional leaf, no exaggerated numbers, no “super-concentrated 7-OH” claims.
Another category you’ll see is states that haven’t banned kratom outright but have singled out synthetic or concentrated forms, often using 7-hydroxymitragynine as the key marker. These laws often say something like “kratom is legal for adults, but synthetic kratom or products with elevated 7-OH are prohibited.”
Recent reporting and legal tracking point to several states in this camp:
Mississippi has cracked down on synthetic kratom extracts and products with high 7-OH content, even as natural kratom remains technically legal in many areas.
Tennessee: Allows natural kratom for adults (often 21+) but bans synthetic 7-OH derivatives under state law.
Texas: As mentioned, it banned synthetic kratom as of late 2025 and limits allowable 7-OH content in kratom products.
Ohio and similar states have taken interim or emergency steps to restrict synthetic or isolated 7-OH while broader kratom rules are under consideration.
According to state-by-state analyses, the justification is almost always the same: natural kratom leaf has a long history of use in low-tech forms, while synthetic 7-OH products look and behave more like unapproved opioid analogs. In our own reviews of state regulatory commentary, officials repeatedly cite concerns about 7-OH’s potency and potential for abuse, especially when consumers have no idea how strong a concentrated extract really is.
If you’re in one of these states, the legality of 7-hydroxymitragynine depends heavily on the form. Natural kratom with trace 7-OH levels backed by a lab report is usually treated differently than a vape cartridge or shot marketed as “extra-strong 7-OH.” The former might be legal and regulated; the latter might cross into controlled-substance territory.
There are still states where kratom and 7-hydroxymitragynine are technically legal and not specifically regulated at the state level, at least not yet. Legal summaries and kratom industry maps often mark these states as “legal” with no statewide restrictions, though bills are frequently introduced and withdrawn as the debate evolves.
In these places, you can generally buy and possess kratom and any naturally occurring 7-OH in the product without violating state law. However, that doesn’t mean it’s a free-for-all. Federal rules on misbranding, adulteration, and unapproved drug claims still apply, and the growing federal focus on concentrated 7-OH means that products featuring isolated or enhanced 7-OH are far riskier than basic leaf.
Moreover, local bans are becoming more common even when states as a whole have not acted. Some cities and counties, for instance, have banned kratom sales while the state keeps it legal. A number of California cities (including San Diego) have adopted local prohibitions despite their legality under state law. Similar local patchworks exist in states like Florida and Mississippi, where kratom might be legal in one county and prohibited in the next.
For residents of these “unregulated” states, the key takeaway is caution. Just because you don’t see a state-level kratom law doesn’t mean your city, county, or local health department hasn’t acted. And if you’re dealing with any product that highlights 7-OH as a concentrated or added ingredient, you should assume it’s on much shakier legal ground than a standard, lab-tested kratom powder.
This isn’t a comprehensive legal table, and laws change quickly, but here’s a simplified snapshot that reflects patterns described in recent legal summaries. Always verify your local law before acting.
Indiana | Banned kratom under controlled substances law | 7-OH treated as controlled along with kratom |
Vermont | Kratom banned through scheduling | 7-OH also banned as part of kratom-related controls |
Nevada | Legal, regulated under KCPA-style framework | Natural 7-OH allowed within tested, regulated products; synthetic/adulterated discouraged |
Utah | Legal, regulated via KCPA; testing and labeling required | 7-OH levels controlled through quality and purity standards |
Texas | Kratom allowed with new restrictions from 2025 | Synthetic kratom banned; 7-OH capped (e.g., products must stay under specific 7-OH thresholds) |
Tennessee | Natural kratom legal for adults (typically 21+) | Synthetic 7-OH and similar derivatives banned |
Mississippi | Legal in many areas but heavily fragmented by local bans | Synthetic/high-7-OH products restricted; local crackdowns common |
California | Statewide legal with local bans in certain cities | 7-OH not separately scheduled statewide; risky in concentrated form due to FDA stance |
Again, treat this as a directional guide, not a legal opinion. State legislatures are moving quickly, especially in response to federal pressure around 7-OH.
One of the most misunderstood parts of this whole discussion is the difference between how regulators view the plant and how they view 7-hydroxymitragynine as a concentrated or synthetic substance. FDA statements and legal analyses consistently make an important distinction:
Natural kratom leaf products are not currently scheduled federally, but they are considered unapproved and potentially unsafe, and the FDA has repeatedly warned against their use.
Concentrated or synthetic 7-OH products are treated as an emerging opioid-like threat and have been singled out for possible Schedule I control.
In 2025, the FDA’s recommendation to schedule 7-OH under the Controlled Substances Act explicitly focused on concentrated kratom derivatives, emphasizing their abuse potential and lack of medical use. Regulatory commentary on that recommendation stressed that the agency was not trying to re-litigate the entire kratom plant at that moment, but instead target the subset of products that concentrate 7-OH far beyond traditional levels.
From a DEA standpoint, this is familiar territory. The agency considered scheduling kratom’s main alkaloids back in 2016 and backed off after public pushback, but the renewed focus on 7-OH reflects a compromise strategy: go after the most potent derivative first, then let states handle the broader kratom question. In our reading of these developments, it’s clear that 7-OH is being positioned as the “low-hanging fruit” for federal control, while kratom itself continues to be fought over at the state level.
For consumers and vendors, this means that products built around concentrated or isolated 7-OH pills, shots, or tinctures labeled primarily by their 7-OH content are likely to be the first casualties of any federal scheduling move. Natural kratom powder with modest, tested 7-OH levels may remain in a gray area, but concentrated 7-OH will almost certainly not.
Because the legal landscape is complicated, a lot of myths circulate in kratom circles. Here are a few we see most often in customer questions and online discussions, along with how they stack up against current information.
First, there’s the idea that “if kratom is legal here, 7-OH is automatically legal too.” That’s not necessarily true. Some states treat kratom leaf and synthetic or concentrated 7-OH completely differently, allowing one and banning or restricting the other. As we’ve seen, states like Tennessee and Texas carve out special rules for synthetic or high-7-OH products even while keeping natural kratom legal for adults.
Another common myth is that “7-OH is just a natural part of the plant, so regulators can’t touch it.” In reality, regulators can and do act on the basis of concentration, synthesis, or form. When 7-OH is present in low, natural levels inside a plant, it’s treated differently than when it’s concentrated, isolated, or synthetically created and sold in powerful extracts. State laws and federal proposals specifically target those concentrated or synthetic forms, not the mere existence of 7-OH within a leaf.
We also see people assume that “there’s no risk as long as there’s a lab test.” Lab testing is crucial for safety and transparency, but it doesn’t override the law. A beautifully formatted COA for a product that violates a state’s 7-OH limit or synthetic ban doesn’t magically make that product legal. What testing does help with is verifying that you’re truly dealing with natural-level 7-OH and not a disguised “extra-strength” extract.
Finally, some believe that “federal rules don’t matter if my state hasn’t banned kratom.” That’s dangerous thinking. Even in states that haven’t regulated kratom, federal law still applies, and the FDA’s stance on concentrated 7-OH and unapproved drug claims can lead to warning letters, product seizures, or other enforcement actions. In other words, you don’t have to be in a “ban” state to see a product pulled off the market if it crosses certain lines.
If you care about staying on the right side of both safety and legality, learning how to read a kratom Certificate of Analysis (COA) is one of the most practical skills you can develop. We’ve reviewed thousands of COAs in our own testing, and the same patterns keep emerging across products that take compliance seriously.
A good COA will clearly list:
The product name and batch/lot number.
The testing lab’s name, contact info, and certification or accreditation details.
Alkaloid levels, including mitragynine and 7-hydroxymitragynine, are clearly labeled units (often mg/g or percentage).
Contaminant testing for heavy metals (like lead, arsenic, cadmium, mercury) and microbial hazards (like Salmonella or E. coli).
A date of testing and a signature or approval mark from the lab.
To evaluate 7-OH specifically, look for its value relative to mitragynine and to typical “natural” levels. Legal analysts have noted that some KCPA-style laws and state rules cap allowable 7-OH content or restrict synthetic enhancements, and legal guidance points to thresholds like 2 percent or less as common benchmarks. If a COA shows unusually high 7-OH values, especially if the product is marketed as an extract, shot, or “extra strong”, you may be looking at a product that’s much closer to the synthetic or concentrated category regulators are targeting.
Also, make sure the COA is batch-specific and up to date. Reused or generic COAs are a red flag. Some states and legal experts have warned about reused lab reports and even outright fake COAs being used to create the illusion of compliance. We’ve seen examples where the same COA is used across multiple products with different labels, which doesn’t pass the smell test. If the vendor can’t provide a matching COA for the batch you’re holding, it’s worth reconsidering your purchase.
Finally, cross-check any bold marketing claims against the COA. If a label brags about “max 7-OH potency” but the COA shows modest, natural levels, something’s off. Conversely, if the COA reveals high 7-OH levels but the vendor pretends it’s just regular kratom, that’s a transparency and possibly a legal problem, especially in states that cap 7-OH or ban synthetics.
Given everything above, how should an everyday kratom user think about 7-hydroxymitragynine legality and risk? You don’t need a law degree, but you do need a basic framework. Here’s a practical way to approach it.
First, know your state, and if possible, your city or county. Check recent state law summaries and kratom legality maps for your area, paying attention to whether your state falls into the “banned,” “regulated/KCPA,” “synthetic-restricted,” or “mostly unregulated” category. Then search specifically for whether your state has mentioned 7-hydroxymitragynine or “synthetic kratom” in any legislation or regulatory rules, because that’s where the nuance lies.
Second, default to natural, lab-tested products from transparent vendors. Legal updates and FDA communications repeatedly flag synthetic or high-potency derivative products as the main public health concern. In our lab reviews, products that stick to simple, well-tested leaf and publish full COAs rarely sit at the center of enforcement stories. It’s almost always the concentrated shots, pills, or vapes with murky 7-OH content that end up in regulatory crosshairs.
Third, avoid products that highlight 7-OH as the primary selling point. Given the FDA’s explicit recommendation to schedule concentrated 7-OH and the trend in states toward banning or capping it, putting your money into products marketed around “pure 7-OH” or similar language is asking for legal and safety trouble. If the product feels more like an experimental opioid analog than a traditional botanical, regulators are likely to treat it that way.
Fourth, treat legal status as only one layer of your decision. Even in states where kratom and 7-OH are still technically unregulated, the absence of law doesn’t mean the presence of safety. In our own testing, we’ve seen big differences in quality, contamination levels, and alkaloid consistency between vendors who invest in full COAs and those who just talk a good game. Your safest bet is to apply a “kratom safety checklist” mindset: transparent lab results, clear labeling, realistic 7-OH levels, and compliance with any state restrictions that exist.
Finally, keep an eye on federal developments. The FDA’s 2025 recommendation regarding 7-OH is not a one-off press release; it’s part of a longer campaign. Legal blogs and regulatory updates expect the DEA to move forward on scheduling decisions, and some states have already cited the FDA’s stance as justification for their own restrictions. If and when 7-hydroxymitragynine is scheduled at the federal level, the entire landscape could shift quickly, particularly for manufacturers and vendors.
So, where does all this leave you if your main question is, “Is 7-hydroxymitragynine legal in the U.S.?” The most accurate, honest answer is: it depends heavily on where you live, what form it’s in, and how it’s being sold. Federally, kratom itself remains unscheduled, but concentrated or synthetic 7-OH is under active scrutiny, with an FDA recommendation on the table to place it into Schedule I. State laws add another layer, ranging from outright bans that encompass 7-OH to regulated frameworks that cap 7-OH levels, to targeted bans on synthetic derivatives while leaving natural kratom legal.
If you stick to natural kratom products from transparent vendors, backed by real COAs and sold in compliance with your state’s rules, you’re aligning with the direction most regulators say they’re comfortable with, at least for now. When you veer into products marketed primarily for their 7-hydroxymitragynine content or try to import concentrated or synthetic 7-OH items into a state that’s already acting against them, you step into a much riskier, often clearly illegal space.
The safest mindset is simple: treat 7-OH as a key legal and safety marker, not just another number on a lab report. Learn your state’s laws, read COAs carefully, and be skeptical of anything that promises more potency than traditional leaf would ever naturally deliver. The legal status of 7-hydroxymitragynine is evolving rapidly, but consumers who stay informed and cautious can navigate this landscape without blindly walking into avoidable trouble.
--- Canonical: https://www.kratomtest.org/blog/is-7-hydroxymitragynine-legal-in-the-u-s-a-state-by-state-reality-check